Suparna Chatterjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suparna Chatterjee has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Avijit Hazra
Department of Pharmacology, Institute of Postgraduate Medical Education & Research, Kolkata, West Bengal, India
6 shared publicationsRicheek Pradhan
A Department of Pharmacology , Institute of Post Graduate Medical Education and Research , Kolkata , India
4 shared publicationsRaja Chakraverty
Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
3 shared publicationsRajni Kaul
ICMR Headquarters New Delhi India
3 shared publicationsShouvik Choudhury
Department of Pharmacology, Burdwan Medical College, Burdwan, West Bengal, India
3 shared publicationsShreya Kotal
Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
3 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Wolters Kluwer Health in Indian Journal of Pharmacology
- Vol. 58 (6) , 744-753
Medication profile and treatment response in acute exacerbation of chronic obstructive pulmonary disease: A prospective longitudinal observational study in a tertiary care hospital
OBJECTIVES: To evaluate the medication use profile, treatment outcomes, and postdischarge responsiveness and adherence in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). MATERIAL AND METHODS: This prospective longitudinal observational study enrolled consenting adults hospitalized for AECOPD at a tertiary care hospital in Kolkata. Medication details (drug, route, dose, frequency, and duration) were recorded from admission to discharge. In-hospital and postdischarge outcomes, symptom burden (Chronic Obstructive Pulmonary Disease Assessment Test [CAT]), quality of life (St. George’s Respiratory Questionnaire), and medication adherence (Medication Adherence Rating Scale-10) were evaluated. Data were analyzed using Jamovi statistical software. RESULTS: Fifty-one participants were enrolled (mean age: 62.9 years, 80.4% males). 76.4% had severe exacerbations (Rome criteria). In-hospital, 98% received parenteral antibiotics (median duration: 8 days), with dual therapy being the most common pattern. In addition, 88.2% received short-course systemic steroids. Bronchodilators, short-acting beta-2 agonists + short-acting muscarinic antagonists and long-acting beta-agonists (LABA) + inhaled corticosteroids (ICS) were initiated in 92.2% and 88.2% of participants, respectively. Following stabilization, 21.6% were started on long-acting muscarinic antagonists (LAMA) therapy in-hospital. Ventilatory support was required by 64.7%, and the in-hospital mortality rate was 23.5%. Admission CAT score was an independent predictor of mortality (adjusted odds ratios: 2.13, 95% confidence interval: 1.21–3.76, P = 0.009). At discharge, inhaled therapy was centered on LABA + ICS inhalers (84.6%), and in 71.8%, a LAMA-based inhaler was added. 43.5% participants required readmission within 6 months. Participants with correct inhaler technique and good medication adherence showed a significant increase from the 1 st to the 6 th month of follow-up ( P < 0.05). CONCLUSIONS: AECOPD pharmacotherapy largely aligned with established guidelines. However, high readmission rates and initial poor inhaler technique highlight the need for prioritized strategies in medication adherence and device training.
- 2 November 2026
- Published by Wolters Kluwer Health in Indian Journal of Pharmacology
- Vol. 58 (6) , 744-753
Open AccessMedication profile and treatment response in acute exacerbation of chronic obstructive pulmonary disease: A prospective longitudinal observational study in a tertiary care hospital
OBJECTIVES: To evaluate the medication use profile, treatment outcomes, and postdischarge responsiveness and adherence in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). MATERIAL AND METHODS: This prospective longitudinal observational study enrolled consenting adults hospitalized for AECOPD at a tertiary care hospital in Kolkata. Medication details (drug, route, dose, frequency, and duration) were recorded from admission to discharge. In-hospital and postdischarge outcomes, symptom burden (Chronic Obstructive Pulmonary Disease Assessment Test [CAT]), quality of life (St. George’s Respiratory Questionnaire), and medication adherence (Medication Adherence Rating Scale-10) were evaluated. Data were analyzed using Jamovi statistical software. RESULTS: Fifty-one participants were enrolled (mean age: 62.9 years, 80.4% males). 76.4% had severe exacerbations (Rome criteria). In-hospital, 98% received parenteral antibiotics (median duration: 8 days), with dual therapy being the most common pattern. In addition, 88.2% received short-course systemic steroids. Bronchodilators, short-acting beta-2 agonists + short-acting muscarinic antagonists and long-acting beta-agonists (LABA) + inhaled corticosteroids (ICS) were initiated in 92.2% and 88.2% of participants, respectively. Following stabilization, 21.6% were started on long-acting muscarinic antagonists (LAMA) therapy in-hospital. Ventilatory support was required by 64.7%, and the in-hospital mortality rate was 23.5%. Admission CAT score was an independent predictor of mortality (adjusted odds ratios: 2.13, 95% confidence interval: 1.21–3.76, P = 0.009). At discharge, inhaled therapy was centered on LABA + ICS inhalers (84.6%), and in 71.8%, a LAMA-based inhaler was added. 43.5% participants required readmission within 6 months. Participants with correct inhaler technique and good medication adherence showed a significant increase from the 1 st to the 6 th month of follow-up ( P < 0.05). CONCLUSIONS: AECOPD pharmacotherapy largely aligned with established guidelines. However, high readmission rates and initial poor inhaler technique highlight the need for prioritized strategies in medication adherence and device training.
- 30 October 2026
- Published by Wolters Kluwer Health in Indian Journal of Dermatology
Effectiveness and Safety of Off-label Tofacitinib Use for Atopic Dermatitis, Alopecia Areata and Plaque Psoriasis: An Observational Study
Background: Tofacitinib is a first-generation janus kinase inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. However, it is also used for several off-label dermatological disorders. Aims and Objectives: To evaluate the effectiveness and safety of off-label use of tofacitinib in alopecia areata, plaque psoriasis and atopic dermatitis. Materials and Methods: This prospective observational study was conducted at a tertiary care hospital. Patients either currently taking tofacitinib for ≤2 weeks or being prescribed the drug for atopic dermatitis (AD), alopecia areata (AA) and plaque psoriasis (PP) were included. Socio-demographic profile, tofacitinib and other drug details were noted. Disease severity scores—SALT (Severity of Alopecia Tool) for AA, PASI (Psoriasis Area and Severity Index) for PP and SCORAD (SCORing Atopic Dermatitis) for AD patients—were recorded at enrolment and at 2, 4 and 8 ± 2 weeks’ visits, respectively. Investigators’ Global Assessment (IGA) and all treatment-emergent adverse effects were also assessed. Results: Thirty patients (13-AA; 9-PP; 8-AD) were enrolled. All were on 5 mg twice daily tofacitinib during the study course. At 8 ± 2 weeks, 13 cases (100%), 9 cases (77.77%), 8 cases (62.5%) and 30 cases (30%) achieved > 50% reduction in SALT, PASI, SCORAD and IGA, respectively. There were statistically significant differences between baseline and the follow-up visits in all disease severity scores, indicating significant clinical improvement. Twelve non-serious adverse drug reactions were noted, which resolved with symptomatic treatment and did not require drug discontinuation. Conclusion: This study generated data to guide clinicians regarding the off-label use of tofacitinib, as it showed promising results with few non-serious adverse effects.
- 30 October 2026
- Published by Wolters Kluwer Health in Indian Journal of Dermatology
Effectiveness and Safety of Off-label Tofacitinib Use for Atopic Dermatitis, Alopecia Areata and Plaque Psoriasis: An Observational Study
Background: Tofacitinib is a first-generation janus kinase inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. However, it is also used for several off-label dermatological disorders. Aims and Objectives: To evaluate the effectiveness and safety of off-label use of tofacitinib in alopecia areata, plaque psoriasis and atopic dermatitis. Materials and Methods: This prospective observational study was conducted at a tertiary care hospital. Patients either currently taking tofacitinib for ≤2 weeks or being prescribed the drug for atopic dermatitis (AD), alopecia areata (AA) and plaque psoriasis (PP) were included. Socio-demographic profile, tofacitinib and other drug details were noted. Disease severity scores—SALT (Severity of Alopecia Tool) for AA, PASI (Psoriasis Area and Severity Index) for PP and SCORAD (SCORing Atopic Dermatitis) for AD patients—were recorded at enrolment and at 2, 4 and 8 ± 2 weeks’ visits, respectively. Investigators’ Global Assessment (IGA) and all treatment-emergent adverse effects were also assessed. Results: Thirty patients (13-AA; 9-PP; 8-AD) were enrolled. All were on 5 mg twice daily tofacitinib during the study course. At 8 ± 2 weeks, 13 cases (100%), 9 cases (77.77%), 8 cases (62.5%) and 30 cases (30%) achieved > 50% reduction in SALT, PASI, SCORAD and IGA, respectively. There were statistically significant differences between baseline and the follow-up visits in all disease severity scores, indicating significant clinical improvement. Twelve non-serious adverse drug reactions were noted, which resolved with symptomatic treatment and did not require drug discontinuation. Conclusion: This study generated data to guide clinicians regarding the off-label use of tofacitinib, as it showed promising results with few non-serious adverse effects.
- Open Access
- 9 May 2026
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 163 (5) , 693-694
Addressing methodological and analytical pitfalls on medical devices related adverse events
Addressing methodological and analytical pitfalls on medical devices related adverse events
- 9 May 2026
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 163 (5) , 693-694
Open AccessAddressing methodological and analytical pitfalls on medical devices related adverse events
Addressing methodological and analytical pitfalls on medical devices related adverse events
- 12 March 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (7) , 2326-2335
Prescribing skills course: Three years' experience and lessons learnt through India's massive open online course
Aim: Studies highlighting the prevalence of inappropriate prescribing and preventable harm emphasize the need to enhance prescribing competencies. This paper describes distinctive features, launch and evaluation of massive open online course (MOOC) Prescribing Skills Course (PSC) designed for medical interns and registered medical practitioners (RMPs). Methods: PSC development funded by Indian Council of Medical Research (ICMR), guided by national and international experts, with content aligned with the national medical curriculum and inputs from stakeholders, included video lectures with case scenarios, demonstration videos, assignments (pre‐ and post‐course MCQ tests, prescription analysis) and structured feedback. Hosted on Government of India's online learning platform, course infrastructure enabled data collection for evaluation and analysis. Results: PSC having 50 modules was conducted with interns' enrolment/completion 4327/1164 (26.9%), 4098/815 (19.9%), 665/ 129 (19.4%) in 2020, 2021, 2022 and RMPs 1984/557(28.1%), 448/138 (30.8%) in 2021, 2022, respectively. Enrolment was significantly lower in regions with weaker health indices (rate ratio 0.35 with 95% CI: 0.32–0.38; P < 0.001; Poisson regression test). Participants rated course content, relevance, quality, assignment usefulness ‘excellent’ to ‘very good’. RMPs demonstrated higher baseline scores and greater improvement (from 60% to 73.3% p < 0.001 in cycle 3) compared to interns. Conclusion: The PSC‐ MOOC is convenient, accessible with experiential learning for large numbers. Performance of RMPs may suggest practical relevance and applicability. Module‐wise performance analysis and enrolment variation provided insights for future strategy. Limitations include inability to assess the impact on prescribing practices. PSC‐MOOC represents a promising, scalable educational strategy. Our experience would be useful to other countries.
- 12 March 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (7) , 2326-2335
Prescribing skills course: Three years' experience and lessons learnt through India's massive open online course
Aim: Studies highlighting the prevalence of inappropriate prescribing and preventable harm emphasize the need to enhance prescribing competencies. This paper describes distinctive features, launch and evaluation of massive open online course (MOOC) Prescribing Skills Course (PSC) designed for medical interns and registered medical practitioners (RMPs). Methods: PSC development funded by Indian Council of Medical Research (ICMR), guided by national and international experts, with content aligned with the national medical curriculum and inputs from stakeholders, included video lectures with case scenarios, demonstration videos, assignments (pre‐ and post‐course MCQ tests, prescription analysis) and structured feedback. Hosted on Government of India's online learning platform, course infrastructure enabled data collection for evaluation and analysis. Results: PSC having 50 modules was conducted with interns' enrolment/completion 4327/1164 (26.9%), 4098/815 (19.9%), 665/ 129 (19.4%) in 2020, 2021, 2022 and RMPs 1984/557(28.1%), 448/138 (30.8%) in 2021, 2022, respectively. Enrolment was significantly lower in regions with weaker health indices (rate ratio 0.35 with 95% CI: 0.32–0.38; P < 0.001; Poisson regression test). Participants rated course content, relevance, quality, assignment usefulness ‘excellent’ to ‘very good’. RMPs demonstrated higher baseline scores and greater improvement (from 60% to 73.3% p < 0.001 in cycle 3) compared to interns. Conclusion: The PSC‐ MOOC is convenient, accessible with experiential learning for large numbers. Performance of RMPs may suggest practical relevance and applicability. Module‐wise performance analysis and enrolment variation provided insights for future strategy. Limitations include inability to assess the impact on prescribing practices. PSC‐MOOC represents a promising, scalable educational strategy. Our experience would be useful to other countries.
- Open Access
- 18 October 2025
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 29 (10) , 888
Author Response: Comment on “A Prospective Study to Assess the Profile and Outcome of Acute Paraquat Poisoning in a Tertiary Care Hospital of West Bengal”
How to cite this article: Kotal S, Chatterjee S, Pain S, Kundu AK. Author Response: Comment on “A Prospective Study to Assess the Profile and Outcome of Acute Paraquat Poisoning in a Tertiary Care Hospital of West Bengal”. Indian J Crit Care Med 2025;29(10):888.
- 18 October 2025
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 29 (10) , 888
Open AccessAuthor Response: Comment on “A Prospective Study to Assess the Profile and Outcome of Acute Paraquat Poisoning in a Tertiary Care Hospital of West Bengal”
How to cite this article: Kotal S, Chatterjee S, Pain S, Kundu AK. Author Response: Comment on “A Prospective Study to Assess the Profile and Outcome of Acute Paraquat Poisoning in a Tertiary Care Hospital of West Bengal”. Indian J Crit Care Med 2025;29(10):888.
- Open Access
- 25 August 2025
- Published by Scientific Scholar in Indian Journal of Physiology and Pharmacology
- Vol. 70, 111-116
Tuberculosis with tofacitinib: Analysis of adverse drug reaction reporting trends in the World Health Organization global drug safety database
Objectives: Tofacitinib, a first-generation Janus Kinase (JAK) inhibitor, was approved in 2012 by the United States Food and Drug Administration for various arthritic disorders. However, it is used for several other indications as well. Tuberculosis (TB) is a listed serious adverse drug reaction of tofacitinib. This study evaluated the global reporting pattern of TB with tofacitinib use in the World Health Organization global drug safety database (VigiBase). Materials and Methods: We performed a Vigilyze search on 21 January 2025 using the following search criteria: Drug-tofacitinib (active ingredient) and Reaction-TB (Preferred Term). The following outcome data were analysed-total number of reports, reporting countries, dechallenge and rechallenge information, seriousness and fatalities. Information component (IC value) and lower bound (IC025) were noted for signal detection. Results: A total of 234 individual case safety reports with TB as an adverse reaction were noted worldwide, and only four were from India. About 68% were healthcare professional reporters. About 45.3% of the patients were in the 45–64 years age-group with female preponderance (67.9%). There were 228 serious cases with four fatalities. The most common co-administered drug was methotrexate (11.5%). The IC value was 2.3, and IC025 was 2.2, indicating that it could be considered statistically as a ‘signal.’ Conclusion: This study highlights the importance of screening and close monitoring of patients on tofacitinib to ensure the early detection of TB. It also re-emphasises the need for routine screening for TB before initiating therapy, especially in countries like India, where the prevalence of TB is high.
- 25 August 2025
- Published by Scientific Scholar in Indian Journal of Physiology and Pharmacology
- Vol. 70, 111-116
Open AccessTuberculosis with tofacitinib: Analysis of adverse drug reaction reporting trends in the World Health Organization global drug safety database
Objectives: Tofacitinib, a first-generation Janus Kinase (JAK) inhibitor, was approved in 2012 by the United States Food and Drug Administration for various arthritic disorders. However, it is used for several other indications as well. Tuberculosis (TB) is a listed serious adverse drug reaction of tofacitinib. This study evaluated the global reporting pattern of TB with tofacitinib use in the World Health Organization global drug safety database (VigiBase). Materials and Methods: We performed a Vigilyze search on 21 January 2025 using the following search criteria: Drug-tofacitinib (active ingredient) and Reaction-TB (Preferred Term). The following outcome data were analysed-total number of reports, reporting countries, dechallenge and rechallenge information, seriousness and fatalities. Information component (IC value) and lower bound (IC025) were noted for signal detection. Results: A total of 234 individual case safety reports with TB as an adverse reaction were noted worldwide, and only four were from India. About 68% were healthcare professional reporters. About 45.3% of the patients were in the 45–64 years age-group with female preponderance (67.9%). There were 228 serious cases with four fatalities. The most common co-administered drug was methotrexate (11.5%). The IC value was 2.3, and IC025 was 2.2, indicating that it could be considered statistically as a ‘signal.’ Conclusion: This study highlights the importance of screening and close monitoring of patients on tofacitinib to ensure the early detection of TB. It also re-emphasises the need for routine screening for TB before initiating therapy, especially in countries like India, where the prevalence of TB is high.
- Open Access
- 18 August 2025
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 29 (8) , 677-683
A Prospective Study to Assess the Profile and Outcome of Acute Paraquat Poisoning in a Tertiary Care Hospital of West Bengal
Paraquat is a toxic herbicide, banned in several countries, but still being used extensively in India. Acute paraquat poisoning (APP) is associated with high case fatality. There is a dearth of prospective studies from India. Objectives of the study were to evaluate the profile and outcome of APP and to corroborate the findings of the urine dithionite test (UDT) with their clinical presentation. This prospective study was undertaken over one year in 2023 in a tertiary care hospital setting. All clinically suspected adult APP cases that were admitted to the hospital were enrolled. Socio-demographic, poisoning profile, clinical features, investigations, and treatment received were recorded till outcome (death/discharge/left against medical advice). In addition, UDT was done on admission. A total of 70 cases were enrolled with a median age of 25 years and male preponderance. The proportion of APP cases amongst all indoor admissions was 5.4 per 10,000. The majority were referral cases and had suicidal intent. Amount of poison consumed ranged from 2 to 250 mL with a median intake of 20 mL. In all cases tested, the UDT was positive. Out of the 39 patients in whom urine testing was done, 25 patients died, and all of them had an interpolated urine paraquat concentration ≥1 μg/mL. Case fatality rate was high, 74.28% (95% CI: 62.22-83.66%), and was attributed mainly to multi-organ failure (lung, liver, and kidney). In our study, it was found that APP was associated with a high case fatality rate and the development of multiorgan dysfunction. The findings of the UDT test corroborated with the clinical presentation. This study has generated evidence of the high burden of APP in our setting. This substantiates the need to consider banning it and promote the use of alternative, less toxic herbicides. Kotal S, Chatterjee S, Pain S, Kundu AK. A Prospective Study to Assess the Profile and Outcome of Acute Paraquat Poisoning in a Tertiary Care Hospital of West Bengal. Indian J Crit Care Med 2025;29(8):677-683.
- 18 August 2025
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 29 (8) , 677-683
Open AccessA Prospective Study to Assess the Profile and Outcome of Acute Paraquat Poisoning in a Tertiary Care Hospital of West Bengal
Paraquat is a toxic herbicide, banned in several countries, but still being used extensively in India. Acute paraquat poisoning (APP) is associated with high case fatality. There is a dearth of prospective studies from India. Objectives of the study were to evaluate the profile and outcome of APP and to corroborate the findings of the urine dithionite test (UDT) with their clinical presentation. This prospective study was undertaken over one year in 2023 in a tertiary care hospital setting. All clinically suspected adult APP cases that were admitted to the hospital were enrolled. Socio-demographic, poisoning profile, clinical features, investigations, and treatment received were recorded till outcome (death/discharge/left against medical advice). In addition, UDT was done on admission. A total of 70 cases were enrolled with a median age of 25 years and male preponderance. The proportion of APP cases amongst all indoor admissions was 5.4 per 10,000. The majority were referral cases and had suicidal intent. Amount of poison consumed ranged from 2 to 250 mL with a median intake of 20 mL. In all cases tested, the UDT was positive. Out of the 39 patients in whom urine testing was done, 25 patients died, and all of them had an interpolated urine paraquat concentration ≥1 μg/mL. Case fatality rate was high, 74.28% (95% CI: 62.22-83.66%), and was attributed mainly to multi-organ failure (lung, liver, and kidney). In our study, it was found that APP was associated with a high case fatality rate and the development of multiorgan dysfunction. The findings of the UDT test corroborated with the clinical presentation. This study has generated evidence of the high burden of APP in our setting. This substantiates the need to consider banning it and promote the use of alternative, less toxic herbicides. Kotal S, Chatterjee S, Pain S, Kundu AK. A Prospective Study to Assess the Profile and Outcome of Acute Paraquat Poisoning in a Tertiary Care Hospital of West Bengal. Indian J Crit Care Med 2025;29(8):677-683.
- Open Access
- 1 March 2025
- Published by Wolters Kluwer Health in Indian Journal of Pharmacology
- Vol. 57 (2) , 83-89
How well do patients understand medication information written in prescriptions? A study from Eastern India
INTRODUCTION: Appropriate understanding of medicine-related advice in a prescription by patients ensures therapeutic compliance and mitigates avoidable medication intake-related errors. AIMS: This study assessed how well patients or their caregivers attending a tertiary care hospital have understood medicine-related information in their outpatient department (OPD) prescription. MATERIALS AND METHODS: This prospective questionnaire-based observational study was conducted on patients attending outpatient clinics of four departments of a tertiary care hospital. The questionnaire had both open and close-ended questions, which assessed understanding of written information related to the prescribed medicines. RESULTS: A total of 380 patients were enrolled in the study. 59.21% (95% CI 54.2–64.04) respondents had an excellent or good understanding of drug dosage. Similarly, 40% (95% CI 35.2–45) about drug frequency and 59.77% (95% CI 54.66–64.7) had excellent understanding of drug duration. However, overall composite understanding of prescriptions was poor in 36.84% (95% CI 32.14–41.8) of study participants. Patients with a higher level of education or from higher socioeconomic groups had a better understanding compared to other educational and socioeconomic categories. Suggestions for better patient understanding included prescriptions in vernacular language and pictorial representations. CONCLUSIONS: The study conducted in a tertiary care public hospital in India, reveals suboptimal understanding of medication-related information in OPD prescriptions. Based on the study outcome, measures have been taken to address the issue. Furthermore, there is a need for designing tailored interventions based on the patient profile attending a healthcare facility to facilitate better understanding.
- 1 March 2025
- Published by Wolters Kluwer Health in Indian Journal of Pharmacology
- Vol. 57 (2) , 83-89
Open AccessHow well do patients understand medication information written in prescriptions? A study from Eastern India
INTRODUCTION: Appropriate understanding of medicine-related advice in a prescription by patients ensures therapeutic compliance and mitigates avoidable medication intake-related errors. AIMS: This study assessed how well patients or their caregivers attending a tertiary care hospital have understood medicine-related information in their outpatient department (OPD) prescription. MATERIALS AND METHODS: This prospective questionnaire-based observational study was conducted on patients attending outpatient clinics of four departments of a tertiary care hospital. The questionnaire had both open and close-ended questions, which assessed understanding of written information related to the prescribed medicines. RESULTS: A total of 380 patients were enrolled in the study. 59.21% (95% CI 54.2–64.04) respondents had an excellent or good understanding of drug dosage. Similarly, 40% (95% CI 35.2–45) about drug frequency and 59.77% (95% CI 54.66–64.7) had excellent understanding of drug duration. However, overall composite understanding of prescriptions was poor in 36.84% (95% CI 32.14–41.8) of study participants. Patients with a higher level of education or from higher socioeconomic groups had a better understanding compared to other educational and socioeconomic categories. Suggestions for better patient understanding included prescriptions in vernacular language and pictorial representations. CONCLUSIONS: The study conducted in a tertiary care public hospital in India, reveals suboptimal understanding of medication-related information in OPD prescriptions. Based on the study outcome, measures have been taken to address the issue. Furthermore, there is a need for designing tailored interventions based on the patient profile attending a healthcare facility to facilitate better understanding.
- Open Access
- 1 May 2024
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 56 (3) , 166-171
Association of TPMT and NUDT15 gene polymorphisms with azathioprine-induced leukopenia: A case–control study in Eastern India
BACKGROUND: Azathioprine (AZA) is a widely used immunosuppressant drug. Leukopenia is a serious adverse effect of the drug which often necessitates dose reduction or drug withdrawal. Predictors of leukopenia include genetic and nongenetic factors. Genetic polymorphism of AZA-metabolizing enzyme, thiopurine S-methyltransferase (TPMT) is well established. There is inconclusive evidence about the role of Nudix hydrolase (NUDT15) gene polymorphism. This case–control study assessed the association of genetic polymorphisms of NUDT15 and TPMT with leukopenia induced by AZA. MATERIALS AND METHODS: Cases were patients on AZA who developed leukopenia (white blood cell count TPMT (3 loci: c238G to C, c460G to A, c719A to G) and NUDT15 (c 415C to T, rs116855232) genotyping were done using TPMT strip assay and polymerase chain reaction–restriction fragment length polymorphism, respectively. Genotype frequencies were noted, and the odds ratio was calculated to determine the association between genotypes and leukopenia. RESULTS: Twenty-nine subjects (15 cases and 14 controls) were enrolled. Statistically significant differences were not observed in the TPMT genotype (*1/*1 and *1/*3C) (P = 0.23) between cases and controls. NUDT15 genotypes (*1/*1 and *1/*3) (P = 0.65) also showed no statistically significant difference between cases and controls. CONCLUSION: The above genotypes do not appear to be associated with AZA-induced leukopenia in an eastern Indian population.
- 1 May 2024
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 56 (3) , 166-171
Open AccessAssociation of TPMT and NUDT15 gene polymorphisms with azathioprine-induced leukopenia: A case–control study in Eastern India
BACKGROUND: Azathioprine (AZA) is a widely used immunosuppressant drug. Leukopenia is a serious adverse effect of the drug which often necessitates dose reduction or drug withdrawal. Predictors of leukopenia include genetic and nongenetic factors. Genetic polymorphism of AZA-metabolizing enzyme, thiopurine S-methyltransferase (TPMT) is well established. There is inconclusive evidence about the role of Nudix hydrolase (NUDT15) gene polymorphism. This case–control study assessed the association of genetic polymorphisms of NUDT15 and TPMT with leukopenia induced by AZA. MATERIALS AND METHODS: Cases were patients on AZA who developed leukopenia (white blood cell count TPMT (3 loci: c238G to C, c460G to A, c719A to G) and NUDT15 (c 415C to T, rs116855232) genotyping were done using TPMT strip assay and polymerase chain reaction–restriction fragment length polymorphism, respectively. Genotype frequencies were noted, and the odds ratio was calculated to determine the association between genotypes and leukopenia. RESULTS: Twenty-nine subjects (15 cases and 14 controls) were enrolled. Statistically significant differences were not observed in the TPMT genotype (*1/*1 and *1/*3C) (P = 0.23) between cases and controls. NUDT15 genotypes (*1/*1 and *1/*3) (P = 0.65) also showed no statistically significant difference between cases and controls. CONCLUSION: The above genotypes do not appear to be associated with AZA-induced leukopenia in an eastern Indian population.
- Open Access
- 1 January 2023
- Published by Medknow in Indian Journal of Transplantation
- Vol. 17 (1) , 42-48
Antihypertensive Drug Usage and Target Blood Pressure Attainment in Postrenal Transplant: A Prospective Study in Indian Population
Introduction: The etiology of hypertension in post renal transplant patients is multifold and effective control of blood pressure (BP) contributes towards proper graft functioning and reduces risk of cardiovascular diseases. This prospective observational study was undertaken to evaluate the prevalence of antihypertensive drug use, the prescribing pattern and trends of blood pressure control in a cohort of post renal transplant patients from eastern India. Materials and Methods: Patients who had undergone renal transplant in this public hospital were enrolled as per eligibility criteria. All enrolled patients were on antihypertensive from at least 3months prior to transplant and were followed upto one year post-transplant. Antihypertensive drug (AHD) and immunosuppressant intake, BP recordings and occurrence of major adverse cardiac events (MACE), if any were noted at each visit. Results: 56 patients were enrolled with a mean age of 33.04 ± 9.96 years, 87.5% were male. 75% were hypertensive at discharge (2-3 weeks post-transplant). Percentage of patients on AHD at 3, 6, 9 and 12 months post-transplant were 83.9%, 82.1%, 75% and 71.4% respectively. Amlodipine was the most common prescribed AHD. Target BP control (≤130/80 mm of Hg) was achieved in 62.5% patients at 1year post-transplant. There were no major adverse cardiac events (MACE) during the study period. Conclusion: In our study comprising of a relatively young cohort of transplant patients from India, hypertension control was well achieved in majority of the subjects and no MACE were noted. Amlodipine was the most commonly used AHD either as monotherapy or in combination with beta-blocker. Long term follow up of this cohort shall provide further insights into the trends of such control.
- 1 January 2023
- Published by Medknow in Indian Journal of Transplantation
- Vol. 17 (1) , 42-48
Open AccessAntihypertensive Drug Usage and Target Blood Pressure Attainment in Postrenal Transplant: A Prospective Study in Indian Population
Introduction: The etiology of hypertension in post renal transplant patients is multifold and effective control of blood pressure (BP) contributes towards proper graft functioning and reduces risk of cardiovascular diseases. This prospective observational study was undertaken to evaluate the prevalence of antihypertensive drug use, the prescribing pattern and trends of blood pressure control in a cohort of post renal transplant patients from eastern India. Materials and Methods: Patients who had undergone renal transplant in this public hospital were enrolled as per eligibility criteria. All enrolled patients were on antihypertensive from at least 3months prior to transplant and were followed upto one year post-transplant. Antihypertensive drug (AHD) and immunosuppressant intake, BP recordings and occurrence of major adverse cardiac events (MACE), if any were noted at each visit. Results: 56 patients were enrolled with a mean age of 33.04 ± 9.96 years, 87.5% were male. 75% were hypertensive at discharge (2-3 weeks post-transplant). Percentage of patients on AHD at 3, 6, 9 and 12 months post-transplant were 83.9%, 82.1%, 75% and 71.4% respectively. Amlodipine was the most common prescribed AHD. Target BP control (≤130/80 mm of Hg) was achieved in 62.5% patients at 1year post-transplant. There were no major adverse cardiac events (MACE) during the study period. Conclusion: In our study comprising of a relatively young cohort of transplant patients from India, hypertension control was well achieved in majority of the subjects and no MACE were noted. Amlodipine was the most commonly used AHD either as monotherapy or in combination with beta-blocker. Long term follow up of this cohort shall provide further insights into the trends of such control.